Proteomics

Dataset Information

0

Proteomic profile of mouse hippocampus following kainate-induced epileptogenesis C4PR_LIV


ABSTRACT: Anti-epileptogenic agents that prevent the development of epilepsy following a brain insult remain the holy grail of epilepsy therapeutics. In order to identify such drugs, it is necessary to first understand the cellular and molecular events that underlie the epileptogenic process, from initial insult to the onset of spontaneous recurrent seizures. We have employed a label-free proteomic approach that allows quantification of large numbers of brain-expressed proteins in a single analysis in the well-established kainate (KA) mouse (C57BL/6J) model of epileptogenesis. In addition, we have incorporated two putative antiepileptogenic drugs, PSD95BP and 1400W, to give an insight into how such agents might ameliorate the epileptogenesis. The test drugs were administered at appropriate time-points after induction of status epilepticus (SE) and animals were euthanized at 7 days, their hippocampi removed, and subjected to LC-MS/MS analysis. A total of 2,579 proteins were identified; their normalized abundance was compared between treatment groups using ANOVA, with correction for multiple testing by false discovery rate. Significantly altered proteins were subjected to gene ontology analysis to look for enrichment of specific biological processes. KA-induced SE was most robustly associated with an increase in proteins involved in neuroinflammation, oxidative stress, cell-cell interactions and synaptic plasticity. Treatment with PSD95BP (Tat-NR2B9c) or an iNOS inhibitor, 1400W modulated several of these proteins. Our observations require validation in a larger-scale investigation, with candidate proteins explored in more detail. Nevertheless, this study has identified several mechanisms by which epilepsy might be developed and several targets for novel drug development.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Brain

SUBMITTER: Deborah Simpson  

LAB HEAD: Thimmasettappa Thippeswamy

PROVIDER: PXD010986 | Pride | 2019-05-23

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
KA + 1400W_Rep1.pride.mgf.gz Mgf
KA + 1400W_Rep2.pride.mgf.gz Mgf
KA + 1400W_Rep3..pride.mgf.gz Mgf
KA + 1400W_Rep4.pride.mgf.gz Mgf
KA + PSD95BP_Rep1.pride.mgf.gz Mgf
Items per page:
1 - 5 of 120
altmetric image

Publications

The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis.

Tse Karen K   Hammond Dean D   Simpson Deborah D   Beynon Robert J RJ   Beamer Edward E   Tymianski Michael M   Salter Michael W MW   Sills Graeme J GJ   Thippeswamy Thimmasettappa T  

Journal of neuroscience research 20190515 11


Antiepileptogenic agents that prevent the development of epilepsy following a brain insult remain the holy grail of epilepsy therapeutics. We have employed a label-free proteomic approach that allows quantification of large numbers of brain-expressed proteins in a single analysis in the mouse (male C57BL/6J) kainate (KA) model of epileptogenesis. In addition, we have incorporated two putative antiepileptogenic drugs, postsynaptic density protein-95 blocking peptide (PSD95BP or Tat-NR2B9c) and a  ...[more]

Similar Datasets

2023-10-12 | E-MTAB-12633 | biostudies-arrayexpress
2023-10-12 | E-MTAB-12634 | biostudies-arrayexpress
2009-05-22 | E-TABM-709 | biostudies-arrayexpress
2013-09-09 | E-GEOD-50079 | biostudies-arrayexpress
2013-09-09 | E-GEOD-50077 | biostudies-arrayexpress
2023-10-24 | PXD043828 | Pride
2013-06-08 | E-GEOD-47752 | biostudies-arrayexpress
2016-09-06 | E-GEOD-75119 | biostudies-arrayexpress
2016-09-06 | E-GEOD-75120 | biostudies-arrayexpress
2010-09-27 | E-GEOD-18727 | biostudies-arrayexpress